Home Search Abstracts Browse Oral Sessions Browse Poster Sessions

 

Session 12-Oral Abstracts
Advances in ART
Wednesday, 9:30 am-12:15 pm; Room 3022
9:30 am         49 First-in-class Inhibitors of LEDGF/p75-integrase Interaction and HIV Replication
Frauke Christ*1, A Voet1, A Marchand1, S Nicolet1, B Desimmie1, D Marchand1, M Demaeyer1, S Strelkov1, P Chaltin2, and Z Debyser1
1Katholieke Univ Leuven, Belgium and 2Ctr for Innovation and Stimulation of Med Devt, Leuven, Belgium
9:45 am         50 Discovery of Potent HIV-1 Capsid Assembly Inhibitors
S Titolo1, J-F Mercier1, E Wardrop1, U von Schwedler2, N Goudreau1, C Lemke1, A-M Faucher1, C Yoakim1, W Sundquist2, and Stephen Mason*1
1Boehringer-Ingelheim Ltd, Laval, Canada and 2Univ of Utah, Salt Lake City, US
10:00 am         51 Instantaneous Inhibitory Potential Is Similar to Inhibitory Quotient at Predicting HIV-1 Response to ART
Timothy Henrich*1,2, H Ribaudo3, and D Kuritzkes1,2
1Brigham and Women’s Hosp, Boston, MA, US; 2Harvard Med Sch, Boston, MA, US; and 3Harvard Sch of Publ Hlth, Boston, MA, US
10:15 am         52 Multiple Equilibrium Model Predicts Class-specific Steep Dose-response Curve Slope for Anti-HIV-1 Drugs
Lin Shen*1, A Rabi1, A Sedaghat1, and R Siliciano1,2
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US and 2Howard Hughes Med Inst, Baltimore, MD, US
10:30 am         53 Safety and Efficacy of TBR 652, a CCR5 Antagonist, in HIV-1-infected, ART-experienced, CCR5 Antagonist-naïve Patients
S Palleja1, Calvin Cohen*2, J Gathe3, M Thompson4, E DeJesus5, C Brinson6, R Elion7, J Galindez8, D Martin1, and J Sapirstein1
1Tobira Therapeutics, Inc, Princeton, NJ, US; 2Community Res Initiative of New England, Boston, MA, US; 3Private Practice, Houston, TX, US; 4AIDS Res Consortium of Atlanta, GA, US; 5Orlando Immunology Ctr, FL, US; 6Central Texas Clin Res, Austin, US; 7Whitman Walker/Elizabeth Taylor Clin, Washington, DC, US; and 8CIBIC, Rosario, Argentina
10:45 am    54LB Phase 3 Trials of Vicriviroc in Treatment-experienced Subjects Demonstrate Safety but Not Significantly Superior Efficacy over Potent Background Regimens Alone
Joseph Gathe*1, R Diaz2, G Fatkenheuer3, J Zeinecker4, C Mak5, R Vilchez5, W Greaves5, S Kumar5, C Onyebuchi5, and L Dunkle5
1Therapeutic Concepts PA, Houston, TX, US; 2Federal Univ of Sao Paulo, Brazil; 3Univ of Cologne, Germany; 4Desmond Tutu HIV Fndn, Cape Town, South Africa; and 5Merck Res Labs, Kenilworth, NJ, US
11:00 am         55 The Discovery of S/GSK1349572: A Once-daily Next Generation Integrase Inhibitor with a Superior Resistance Profile
Brian Johns*1, T Kawasuji2, T Taishi2, H Yoshida2, E Garvey1, W Spreen1, M Underwood1, A Sato2, T Yoshinaga2, and T Fujiwara2
1GlaxoSmithKline, Research Triangle Park, NC, US and 2Shionogi & Co, Ltd, Osaka, Japan
11:15 am         56 Risk of WHO 4 Events and Death by Current CD4 on ART in the DART Trial: The Impact of CD4-dependent Reporting Bias
Ann Sarah Walker*1, A Babiker1, C Kityo2, J Hakim3, P Munderi4, F Ssali2, A Reid3, H Grosskurth4, C Gilks5, T Peto6, and the DART Trial Team
1Med Res Council Clin Trials Unit, London, UK; 2Joint Clin Res Ctr, Kampala, Uganda; 3Univ of Zimbabwe, Harare; 4Med Res Council/Uganda Virus Res Inst, Entebbe; 5Imperial Coll London, UK; and 6Univ of Oxford, UK
11:30 am         57 Efficacy and Safety at 48 Weeks of Once-daily vs Twice-daily DRV/r in Treatment-experienced HIV-1+ Patients with No DRV Resistance-associated Mutations: The ODIN Trial
Pedro Cahn*1, J Fourie2, B Grinsztejn3, S Hodder4, J-M Molina5, K Ruxrungtham6, C Workman7, T Van de Casteele8, P De Doncker8, and F Tomaka9
1Fndn Huesped, Buenos Aires, Argentina; 2Med Res Council, Tygerberg, South Africa; 3Inst de Pesquisa Clin Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil; 4Univ of Med and Dentistry of New Jersey, Newark, US; 5Hosp St-Louis, Paris, France; 6Thai Red Cross AIDS Res Ctr, Chulalongkorn Univ, Bangkok; 7Ground Zero Med Ctr, Darlinghurst, Australia; 8Tibotec BVBA, Mechelen, Belgium; and 9Tibotec Inc, Yardley, PA, US
11:45 am    58LB Single-tablet, Fixed-dose Regimen of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Achieves a High Rate of Virologic Suppression and GS-9350 Is an Effective Booster
Calvin Cohen*1, D Shamblaw2, P Ruane3, R Elion4, E DeJesus5, H Liu6, L Zhong6, D Warren6, B Kearney6, and S Chuck6
1Community Res Initiative of New England, Boston, MA, US; 2San Diego, CA, US; 3Los Angeles, CA, US; 4Whitman Walker Clin, Washington, DC, US; 5Orlando Immunology Ctr, FL, US; and 6Gilead Sci, Foster City, CA, US
12:00 pm    59LB ACTG 5202: Final Results of ABC/3TC or TDF/FTC with either EFV or ATV/r in Treatment-naive HIV-infected Patients
Eric Daar*1, C Tierney2, M Fischl3, A Collier4, K Mollan2, C Budhathoki2, C Godfrey5, N Jahed6, D Katzenstein7, P Sax8, and ACTG A5202 Study Team
1Los Angeles Biomed Res Inst at Harbor-UCLA, Torrance, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Miami Miller Sch of Med, FL, US; 4Harborview Med Ctr, Univ of Washington, Seattle, US; 5Div of AIDS, NIH, Bethesda, MD, US; 6Social & Sci Systems, Inc, Silver Spring, MD, US; 7Stanford Univ, CA, US; and 8Brigham and Women`s Hosp, Harvard Med Sch, Boston, MA, US